Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder
| Status: | Archived |
|---|---|
| Conditions: | Anxiety, Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2011 |
| End Date: | December 2012 |
Imaging Serotonin 5-HT1A Receptors in the High Affinity State in Brains of Patients With Major Depressive Disorder
Background:
- Medications to treat major depression act on a brain chemical called serotonin, which
binds to receptors on brain cells. More research is needed on how serotonin receptors work
in the brain, and imaging studies such as magnetic resonance imaging (MRI) can provide
information on how these receptors function in the brains of individuals with depression and
healthy volunteers. The experimental radioactive chemical [11C]CUMI has been designed to
react with serotonin receptors, and researchers are interested in studying its effectiveness
using positron emission tomography (PET) scanning to see how well it gets into the brain.
Objectives:
- To evaluate the effectiveness of the radiotracer [11C]CUMI in brain imaging studies of
serotonin receptors.
Eligibility:
- Individuals between 18 and 55 years of age who either have been diagnosed with major
depressive disorder or are healthy volunteers.
Design:
- Participants will be screened with a full medical history, physical and psychiatric
examination, blood and urine tests, and questionnaires about mood. Participants will
also have an electrocardiogram at this visit.
- At the first study visit, participants will have a MRI scan of the brain to provide
baseline data on brain function.
- At the second study visit, participants will have a PET scan with the [11C]CUMI
contrast agent.
- No treatment will be provided as part of this protocol....
Eighteen million people in the United States are currently suffering from Major Depressive
Disorder, which is characterized by episodes of low mood, poor self attitude and poor
vitality. Of those suffering from Major Depressive Disorder (MDD), only one third
completely improve, but even among these cases, there is a waiting period of several weeks
or more during which antidepressants take effect. Our inability to adequately treat MDD is
evident in its being ranked number one in Disability Adjusted Life Years (DALY) among
persons aged 15-44. Given this profound burden, improving our understanding of the
molecular basis of MDD is of utmost importance in the development of novel antidepressant
medications.
Serotoninergic neurotransmission is implicated in MDD, as demonstrated by the relative
success of selective serotonin reuptake inhibitors (SSRIs). SSRIs block the reuptake of
serotonin through the serotonin transporter, which then increases serotonin at the synaptic
cleft. Serotonin then binds to 5-HT1A receptors, which are G-protein coupled receptors that
are present both presynaptically and postsynaptically. Presynaptically, these receptors act
as autoinhibitory receptors, triggering decreased firing rates and serotonin release. This
autoinhibition, which lasts for about two weeks, is believed to be the reason why patients
experience a delay in symptomatic improvement after initiation of SSRIs. Serotonin binding
to postsynaptic receptors mediates symptomatic improvement of depression. Multiple positron
emission tomography (PET) studies utilizing antagonists at 5-HT1A have been conducted. The
results are mixed, with some noting increased and others noting decreased 5-HT1A in the
brains of patients with MDD. While clinical heterogeneity and the effects of previous
treatment with SSRIs may be confounding factors, the lack of consistent finding could also
be secondary to using antagonist rather than agonist radioligands. Unlike agonists,
antagonists are unable to discriminate between 5-HT1A in the high and low affinity states,
and only the high affinity state, which is G-protein-coupled, allows for activity at the
5-HT1A receptor.
We propose a PET study using 5-HT1A radiolabelled agonist, C(11)CUMI, to determine whether
there is a difference in the density and distribution of 5-HT1A in the high affinity state
in the brains of patients with MDD versus controls. We will perform an internal control at
1-5 days after initiation of SSRI to determine whether increased serotonin causes detectable
displacement of C(11)CUMI. At 4-8 weeks after initiation of SSRI treatment, we will reimage
patients to determine whether there is a change in the density of 5-HT1A in the high
affinity state.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
301-496-2563
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
Click here to add this to my saved trials
